- Home
- TRC vs PRTA Comparison
TRC vs PRTA Comparison
Compare TRC & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRC
- PRTA
- Stock Information
- Founded
- TRC 1843
- PRTA 2012
- Country
- TRC United States
- PRTA Ireland
- Employees
- TRC 88
- PRTA N/A
- Industry
- TRC Real Estate
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- TRC Finance
- PRTA Health Care
- Exchange
- TRC Nasdaq
- PRTA Nasdaq
- Market Cap
- TRC 419.0M
- PRTA 472.1M
- IPO Year
- TRC N/A
- PRTA N/A
- Fundamental
- Price
- TRC $15.97
- PRTA $10.27
- Analyst Decision
- TRC
- PRTA Buy
- Analyst Count
- TRC 0
- PRTA 9
- Target Price
- TRC N/A
- PRTA $16.14
- AVG Volume (30 Days)
- TRC 85.5K
- PRTA 562.3K
- Earning Date
- TRC 11-06-2025
- PRTA 11-06-2025
- Dividend Yield
- TRC N/A
- PRTA N/A
- EPS Growth
- TRC N/A
- PRTA N/A
- EPS
- TRC N/A
- PRTA N/A
- Revenue
- TRC $45,307,000.00
- PRTA $10,341,000.00
- Revenue This Year
- TRC N/A
- PRTA N/A
- Revenue Next Year
- TRC N/A
- PRTA $602.32
- P/E Ratio
- TRC N/A
- PRTA N/A
- Revenue Growth
- TRC 14.79
- PRTA N/A
- 52 Week Low
- TRC $14.71
- PRTA $4.32
- 52 Week High
- TRC $19.39
- PRTA $18.78
- Technical
- Relative Strength Index (RSI)
- TRC 49.51
- PRTA 54.22
- Support Level
- TRC $15.44
- PRTA $10.34
- Resistance Level
- TRC $16.00
- PRTA $11.17
- Average True Range (ATR)
- TRC 0.34
- PRTA 0.53
- MACD
- TRC 0.04
- PRTA -0.06
- Stochastic Oscillator
- TRC 56.99
- PRTA 31.73
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.